328 related articles for article (PubMed ID: 14764655)
1. Progress and challenges in screening for early detection of ovarian cancer.
Jacobs IJ; Menon U
Mol Cell Proteomics; 2004 Apr; 3(4):355-66. PubMed ID: 14764655
[TBL] [Abstract][Full Text] [Related]
2. Early detection of ovarian cancer.
Badgwell D; Bast RC
Dis Markers; 2007; 23(5-6):397-410. PubMed ID: 18057523
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Menon U; Gentry-Maharaj A; Hallett R; Ryan A; Burnell M; Sharma A; Lewis S; Davies S; Philpott S; Lopes A; Godfrey K; Oram D; Herod J; Williamson K; Seif MW; Scott I; Mould T; Woolas R; Murdoch J; Dobbs S; Amso NN; Leeson S; Cruickshank D; McGuire A; Campbell S; Fallowfield L; Singh N; Dawnay A; Skates SJ; Parmar M; Jacobs I
Lancet Oncol; 2009 Apr; 10(4):327-40. PubMed ID: 19282241
[TBL] [Abstract][Full Text] [Related]
4. Prevention and early detection of ovarian cancer: mission impossible?
Bast RC; Brewer M; Zou C; Hernandez MA; Daley M; Ozols R; Lu K; Lu Z; Badgwell D; Mills GB; Skates S; Zhang Z; Chan D; Lokshin A; Yu Y
Recent Results Cancer Res; 2007; 174():91-100. PubMed ID: 17302189
[TBL] [Abstract][Full Text] [Related]
5. Screening for ovarian cancer in the general population.
Chu CS; Rubin SC
Best Pract Res Clin Obstet Gynaecol; 2006 Apr; 20(2):307-20. PubMed ID: 16364690
[TBL] [Abstract][Full Text] [Related]
6. New tumor markers: CA125 and beyond.
Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
[TBL] [Abstract][Full Text] [Related]
7. Use of proteomic patterns in serum to identify ovarian cancer.
Petricoin EF; Ardekani AM; Hitt BA; Levine PJ; Fusaro VA; Steinberg SM; Mills GB; Simone C; Fishman DA; Kohn EC; Liotta LA
Lancet; 2002 Feb; 359(9306):572-7. PubMed ID: 11867112
[TBL] [Abstract][Full Text] [Related]
8. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R
Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595
[TBL] [Abstract][Full Text] [Related]
9. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
[TBL] [Abstract][Full Text] [Related]
10. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Moore LE; Pfeiffer RM; Zhang Z; Lu KH; Fung ET; Bast RC
Cancer; 2012 Jan; 118(1):91-100. PubMed ID: 21717433
[TBL] [Abstract][Full Text] [Related]
11. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
12. [Identification of new ovarian cancer biomarkers with proteomic analyses--the diagnostic tool of the future?].
Petri AL; Høgdall E; Engelholm SA; Christensen IJ; Kjaer SK; Høgdall CK
Ugeskr Laeger; 2007 Aug; 169(33):2614-9. PubMed ID: 17725906
[TBL] [Abstract][Full Text] [Related]
13. Screening postmenopausal women for ovarian cancer: a systematic review.
Fung MF; Bryson P; Johnston M; Chambers A;
J Obstet Gynaecol Can; 2004 Aug; 26(8):717-28. PubMed ID: 15307976
[TBL] [Abstract][Full Text] [Related]
14. Screening for ovarian cancer in the general population.
Gentry-Maharaj A; Menon U
Best Pract Res Clin Obstet Gynaecol; 2012 Apr; 26(2):243-56. PubMed ID: 22182415
[TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer screening--current status, future directions.
Menon U; Griffin M; Gentry-Maharaj A
Gynecol Oncol; 2014 Feb; 132(2):490-5. PubMed ID: 24316306
[TBL] [Abstract][Full Text] [Related]
16. Screening for Ovarian Cancer in the General Population: State of Art and Perspectives of Clinical Research.
Gadducci A; Cosio S
Anticancer Res; 2022 Sep; 42(9):4207-4216. PubMed ID: 36039417
[TBL] [Abstract][Full Text] [Related]
17. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
Clarke CH; Yip C; Badgwell D; Fung ET; Coombes KR; Zhang Z; Lu KH; Bast RC
Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402
[TBL] [Abstract][Full Text] [Related]
18. Screening for ovarian cancer.
Lewis S; Menon U
Expert Rev Anticancer Ther; 2003 Feb; 3(1):55-62. PubMed ID: 12597350
[TBL] [Abstract][Full Text] [Related]
19. Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Henderson JT; Webber EM; Sawaya GF
JAMA; 2018 Feb; 319(6):595-606. PubMed ID: 29450530
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
